Molecular characterization of anastrozole resistance in breast cancer: Pivotal role of the Akt/mTOR pathway in the emergence of <i>de novo</i> or acquired resistance and importance of combining the allosteric Akt inhibitor MK‐2206 with an aromatase inhibitor
Paul Vilquin(Université Claude Bernard Lyon 1), Pascale A. Cohen(Lyon 1 Université), Thomas Bachelot(Centre Léon Bérard), Julie A. Vendrell(Inserm), Sandra E. Ghayad(Inserm), Isabelle Treilleux(Centre Léon Bérard), Laura Corbo(Centre National de la Recherche Scientifique), Pierre-Étienne Heudel(Centre National de la Recherche Scientifique), Marie Villedieu(Cancers et Préventions), Sabrina Ben Larbi(Lyon 1 Université), Evelyne Grisard(Lyon 1 Université)
Cited by 47
Related Papers
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
|Annals of Oncology|2021|577
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
|The Lancet Oncology|2014|410
SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas
|Nature Genetics|2015|375
Cracking the Estrogen Receptor's Posttranslational Code in Breast Tumors
|Endocrine Reviews|2011|302